JP7358451B2 - 安定な濃厚放射性核種錯体溶液 - Google Patents

安定な濃厚放射性核種錯体溶液 Download PDF

Info

Publication number
JP7358451B2
JP7358451B2 JP2021504214A JP2021504214A JP7358451B2 JP 7358451 B2 JP7358451 B2 JP 7358451B2 JP 2021504214 A JP2021504214 A JP 2021504214A JP 2021504214 A JP2021504214 A JP 2021504214A JP 7358451 B2 JP7358451 B2 JP 7358451B2
Authority
JP
Japan
Prior art keywords
stabilizer
solution
concentration
dota
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500355A (ja
Inventor
テソリエレ，ジョヴァンニ
マリアーニ，マウリツィオ
フガッザ，ロレンツァ
パロ，フランチェスコ デ
バーベイト，ドナート
チッコ，ダニエラ
ブランバーティ，クレメンティーナ
Original Assignee
アドバンスド アクセラレーター アプリケーションズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスド アクセラレーター アプリケーションズ filed Critical アドバンスド アクセラレーター アプリケーションズ
Publication of JP2022500355A publication Critical patent/JP2022500355A/ja
Priority to JP2023085502A priority Critical patent/JP2023126209A/ja
Application granted granted Critical
Publication of JP7358451B2 publication Critical patent/JP7358451B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021504214A 2018-07-25 2018-07-25 安定な濃厚放射性核種錯体溶液 Active JP7358451B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023085502A JP2023126209A (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (fr) 2018-07-25 2018-07-25 Solutions complexes de radionucléides, stables, concentrées

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023085502A Division JP2023126209A (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Publications (2)

Publication Number Publication Date
JP2022500355A JP2022500355A (ja) 2022-01-04
JP7358451B2 true JP7358451B2 (ja) 2023-10-10

Family

ID=63371737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504214A Active JP7358451B2 (ja) 2018-07-25 2018-07-25 安定な濃厚放射性核種錯体溶液
JP2023085502A Pending JP2023126209A (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023085502A Pending JP2023126209A (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Country Status (3)

Country Link
JP (2) JP7358451B2 (fr)
AR (1) AR119655A1 (fr)
WO (1) WO2020021310A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
CN118159303A (zh) * 2022-02-04 2024-06-07 先进加速器应用公司 用于大规模合成放射性核素络合物的方法
CN117159753A (zh) * 2022-04-20 2023-12-05 北京先通国际医药科技股份有限公司 放射性标记的伊文思蓝衍生物药物的制备方法及用途
WO2023202730A2 (fr) * 2022-04-20 2023-10-26 北京先通国际医药科技股份有限公司 Solution aqueuse pharmaceutique dérivée de bleu d'evans radioactif, son procédé de préparation et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (fr) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Utilisation de l'éthanol pour stabiliser une formulation liquide d'un peptide radiomarqué en flacon unique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102484725B1 (ko) * 2016-11-04 2023-01-06 클라리티 파마슈티컬스 리미티드 방사선 요법 및 진단 영상용 제형

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (fr) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Utilisation de l'éthanol pour stabiliser une formulation liquide d'un peptide radiomarqué en flacon unique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Biotherapy and Radiopharmaceuticals, 2017.11, Vol.32, pp.266-273
J. Radioanal. Nucl. Chem., 2014, Vol.302, pp.889-894
J. Radioanal. Nucl. Chem., 2017.11, Vol.314, pp.2181-2188, <DOI 10.1007/s10967-017-5595-1>
Journal of Radioanalytical and Nuclear Chemistry, 2007, Vol.273, No.3, pp.689-694
Majalah Polimer Indonesia, Vol.19, No.1, 2016, pp.1-14
PRODUCTION and QUALITY CONTROL of 177Lu-DOTATATE [177Lu-DOTA-Tyr3]- OCTREOTATE: CLINICAL APPLICATION [retrieved on 2022/04/20], 2009，<https://inis.iaea.org/collection/NCLCollectionStore/_Public/43/004/43004240.pdf>

Also Published As

Publication number Publication date
AR119655A1 (es) 2022-01-05
JP2022500355A (ja) 2022-01-04
WO2020021310A1 (fr) 2020-01-30
JP2023126209A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7358451B2 (ja) 安定な濃厚放射性核種錯体溶液
US20210379212A1 (en) Stable, concentrated radionuclide complex solutions
BR112021007851A2 (pt) método para síntese de um complexo de radionuclídeo e solução farmacêutica aquosa
ES2314977T3 (es) Agentes radioterapeuticos que contienen estaño-117m.
JP7305699B2 (ja) 放射性同位体用ｄｏｔｍｐキット製剤
JP7068222B2 (ja) 高純度治療用骨剤
KR100691745B1 (ko) 테크네튬-99ｍ이 표지된 유기 게르마늄 화합물나노콜로이드, 이의 제조방법 및 용도
Müller et al. Targeted radiotherapeutics from'bench-to-bedside'
Nanabala et al. Preparation of [177Lu] PSMA-617 using carrier added (CA) 177Lu for radionuclide therapy of prostate cancer
EA008195B1 (ru) Применение тория-227 в лучевой терапии заболеваний мягких тканей
EP1004321B1 (fr) Medicament radioactif stable
Elboga et al. An automated synthesis of 177 Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical.
US20240042067A1 (en) [177lu] lutetium-psma i&amp;t composition, kit, method of making, and method of using thereof
Carollo et al. Lutetium-177 labeled peptides: the European Institute of oncology experience
US20230248853A1 (en) Method and device for direct production of radio-isotope based cancer treatment pharmaceuticals
US20240139354A1 (en) Particles functionalized with imageable radioisotopes and methods of making and use thereof
TW201726180A (zh) 同位素製備法
US11813339B2 (en) Method of use for therapeutic bone agents
JP2023135733A (ja) ジルコニウム錯体およびその合成方法
Vagahasiya et al. RADIOPHARMACEUTICAL IN NUCLEAR PHARMACY & MEDICINE AND THEIR THERAPEUTICS APPLICATION IN HEALTH CARE SYSTEM
JP2023539893A (ja) ６４Ｃｕ－ＤＯＴＡＴＡＴＥのスケールアップのための放射標識および製剤化
WO2023164769A1 (fr) Produits radiopharmaceutiques et méthodes
TW202304531A (zh) 放射性配體顯像劑在前列腺癌的用途及注射或輸液用溶液

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210416

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358451

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150